Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03225872 · ClinicalTrials.gov registry record
Biology of Osteosarcoma (BOOST) Registry and Biobank
A clinical trial, sponsored by University of Minnesota.
- Completed
- Registry status
- 362
- Enrollment target
NCT03225872: Completed study, sponsored by University of Minnesota.
NCT03225872 is a clinical trial that has completed, run by University of Minnesota. The registered enrollment target is 362 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03225872 has completed, sponsored by University of Minnesota.
- COMPLETED
- Registry status
- 362 participants
- Enrollment target
Study Summary
Osteosarcoma is very rare cancer of the bone. The investigator started the BOOST registry and biobank to make sure every patient has the opportunity to participate in research.
Primary Outcome
To do this the investigator will compare the genes of people with osteosarcoma to the genes of people who do not have these conditions.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 362 participants |
| Start Date | 2017-01-03 |
| Est. Completion | 2020-01-27 |
What the finished NCT03225872 record still lists
NCT03225872 is an observational study that tracks outcomes without assigning an intervention. The registered 362 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT03225872 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03225872 about?
NCT03225872 is a clinical study titled "Biology of Osteosarcoma (BOOST) Registry and Biobank". Osteosarcoma is very rare cancer of the bone. The investigator started the BOOST registry and biobank to make sure every patient has the opportunity to participate in research.
What is the current status of trial NCT03225872?
This trial is currently completed. The enrollment target is 362 participants. The study started on 2017-01-03. Estimated completion is 2020-01-27.
Who is sponsoring clinical trial NCT03225872?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04988555 · 362 participants · Phase 1
A Study of DSP-5336 in Relapsed/Refractory AML/ ALL With or Without MLL Rearrangement or NPM1 Mutation
- NCT05536141 · 362 participants · Phase 1
A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors
- NCT06534983 · 362 participants · Phase 2
A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran With Nivolumab Versus Nivolumab Alone in Participants With High-risk Muscle-invasive Urothelial Carcinoma (MIUC)
- NCT06472245 · 363 participants · Phase 3
Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI